Outcome of two pairs of monozygotic twins with pleuropulmonary blastoma: case report

Shihan Zhang¹, Xisi Wang¹, Sihui Li², Siyu Cai³, Tong Yu⁴, Libing Fu⁵, Na Zhang⁶, Xiaoxia Peng³, Qi Zeng⁶ and Xiaoli Ma¹*

Abstract

Background: Pleuropulmonary blastomas (PPB) are rare aggressive paediatric lung malignancies and are among the most common DICER1-related disorders: it is estimated that 75–80% of children with a PPB have the DICER1 mutation. DICER1 mutations are responsible for familial tumour susceptibility syndrome with an increased risk of tumours. In approximately 35% of families with children manifesting PPB, further malignancies may be observed. Symptoms of DICER1 syndrome may vary, even within monozygotic twins. Preventive screening of carriers with DICER1 mutations is important and follow-up is undertaken as recommended by the 2016 International PPB Register.

Case presentation: We present two pairs of monozygotic twins. In one pair of 4-year, 2-month old girls, both with DICER1 mutation, one developed PPB(II) and her identical sibling had acute transient hepatitis. In the other pair of 19-month-old female babies, one had a history of bronchopulmonary hypoplasia and developed PPB(III) without DICER1 mutation, and her identical sibling had allergic asthma. Both patients with PPB were treated with R0 resection and received 12 cycles of postoperative chemotherapy. At the most recent review, the twins had been followed up for six and eight years, respectively, and they all remained healthy. However, the height and weight of the patients with PPB were lower than those of their respective identical sister.

Conclusions: PPB is rare, especially in monozygotic twins. We emphasise the importance of genetic testing and follow-up in monozygotic twins with PPB. During the follow-up, children surviving PPB should be monitored closely for growth and development disorders which caused by chemotherapy.

Keywords: Monozygotic twins, Pleuropulmonary blastoma, Long-term survival

Background

Pleuropulmonary blastoma (PPB) is a potentially aggressive, rare childhood neoplasm. It is the most common primary malignant lung tumour in children [1]. PPB is classified into three main types: type I is purely cystic; type II is mixed cystic and solid; and type III is an entirely solid and typically aggressive sarcoma [2]. The type of PPB correlates to the age of diagnosis and prognosis. The 5-year disease-free survival (DFS) and overall survival (OS) rates for Type I PPB are 82 and 91% respectively [3]. For Type II and Type III PPB, the 5-year DFS rate is 59 and 37%, respectively, and the 5-year OS rate is 71 and 53%, respectively [3]. A single-centre report of 41 cases with Type I, II and III PPB in our hospital revealed that the 5-year survival rate was 100, 66.7, and 66.7%, respectively, and the 5-year DFS rate was 100, 66.7 and 55.6%, respectively [4].

* Correspondence: mxl1123@vip.sina.com

¹Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children, Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
PPB has been linked to the mutation of *DICER1* as part of a predisposition syndrome for different types of tumours [5]. PPB is one of the most important causes of *DICER1*-associated morbidity and mortality. While it is uncommon to have more than one individual in a family diagnosed with PPB, some of the other conditions associated with a germline *DICER1* pathogenic variants (e.g., nodular hyperplasia of the thyroid, benign lung cysts) may have a higher penetrance.

Pathogenic germline *DICER1* variants cause a hereditary cancer predisposition syndrome with a variety of manifestations [6]. The risk for most *DICER1*-associated neoplasms is highest in early childhood and decreases in adulthood. Current consensus guidelines for the surveillance of individuals with a *DICER1* pathogenic variant suggest that chest x-ray (CXR) every 6 months from ages 0–7, and then annually from ages 8–12 [7] is vital for improving PPB prevention, surveillance, treatment and follow-up.

**Case presentation**

**Case 1**

As described previously [8], a girl aged 4 years and 2 months old (Twin1) was diagnosed with PPB Type II. She underwent left lower lobectomy with complete removal (R0 resection) at diagnosis and then completed 12 cycles of chemotherapy with IVADo (ifosfamide, vincristine, actinomycin D), resulting in cumulative doses of ifosfamide and doxorubicin of 48 g/m² and 240 mg/m². No second surgery was performed. Her older sister (Twin2) developed acute transient hepatitis at about 5 years of age. Their family history showed that their mother and two aunts had thyroid nodules and their maternal grandmother died of thyroid cancer. Analysis of peripheral blood samples revealed a germline *DICER1* mutation: c.C3675A (p.Y1225X) in the twins and their mother [8].

**Outcome and follow-up**

At the most recent follow-up, the twins were about 10 years old and had been followed up for about 74 months. They remained healthy without heart, liver, kidney dysfunction and scoliosis. Twin1’s height and weight were around the 85th and 40th percentile, respectively, and Twin2’s height and weight were around the 92nd and 64th percentile, respectively. Both Twin1 and Twin2 remained healthy at their last review. Follow-up imaging to monitor for pulmonary disease will include chest computed tomography (CT) for tumour recurrence and MRI for brain metastasis in Twin1. In Twin1 and Twin2, both of whom had confirmed *DICER1* mutation, ultrasound (US) of thyroid and ovaries are recommended every 3 to 5 years and every 6 to 12 months beginning at age 8–10 years, respectively.

**Case 2**

A 19-month-old female baby (Twin3) was referred to our hospital for cough, fever and tachypnoea. A US examination revealed a 9.2 × 10.8 × 16.8 cm liquid zone in the left hemithorax with a 7.6 × 6.9 × 6.1 cm irregular solid lesion inside, and an enhanced chest (CT) scan revealed a 5.9 × 4.8 × 7.6 cm heterogeneous solid lesion with CT value 46 HU, within which multiple cystic liquefaction foci could be observed (Fig. 1).

Twin3 underwent complete resection (R0 resection) at diagnosis, with a large solid tumour measuring 9 × 6 × 5 cm resected from the left lung. Immunohistochemical staining showed Vimentin(+), Ki-67(3%+), EMA(+), NSE(+), Desmin(−), S-100(−), Myo(−), CK(−), SMA(−), SYN(−), CgA(−), CD34(−), CD31(−). Morphological and immunohistochemical features of the resected mass suggested the diagnosis of PPB type III. Abdominal ultrasonography, bone marrow aspiration and cranial MRI detected no metastatic lesions. As PPBs are relatively chemo-sensitive tumours, Twin3 successfully completed 12 cycles of post-operative chemotherapy according to the international PPB chemotherapy regimen IVADo (ifosfamide, vincristine, actinomycin D, doxorubicin) and IVA (ifosfamide, vincristine, actinomycin D). No second surgery was performed.

The identical twins were born with birth weights of 1550 g (Twin 3) and 1450 g (Twin4). Twin3 was diagnosed with bronchopulmonary hypoplasia due to dyspnoea and hospitalised for 27 days in the neonatal department after birth, Twin4 was allergic to mould and she had allergic asthma. Analysis of peripheral blood samples revealed no *DICER1* mutations in these twins.

**Outcome and follow-up**

At the most recent follow-up, the twins were about 9 years old and had been followed up for 99 months. Twin3 was doing well clinically and has remained disease-free for 8 years. Her height and weight were around the 74th and 8th percentile, respectively. Her younger sister (Twin4) had also remained healthy, including with improvement of her allergic asthma. Her height and weight were around the 83th and 12th percentile, respectively. Both twins had no heart, liver, kidney dysfunction and scoliosis. Follow-up imaging to monitor for recurrent pulmonary disease will include chest CT every 3 months in the first year after drug withdrawal, then every 6 months in years 2–4 after drug withdrawal. MRI to check for brain metastasis if had recurrence.

**Discussion and conclusions**

Pathogenic germline *DICER1* variants cause a hereditary cancer predisposition syndrome with a variety of manifestations [9]. *DICER1* tumour predisposition (DICER1)
is characterised by an increased risk for PPB, thyroid gland neoplasia (multinodular goitre, adenomas and thyroid cancer), ovarian tumours (Sertoli-Leydig cell tumours, gynandroblastoma and sarcoma) and cystic nephroma. PPB occurs primarily in very young children, with a study reporting that Type I PPB becomes evident in infants and young children (median age at diagnosis: 8 months) [10], Type II PPB presents at a median age of 35 months and Type III PPB presents at a median age of 41 months [10]. Sertoli-Leydig cell tumours (SLCT) can occur at any age, most often in adolescents and young adults [7]. Cystic nephroma is most common in children younger than 4 years of age, although DICER1-associated cystic nephroma has also occurred in adolescents. Less commonly observed tumours include ciliary body medulloepithelioma (CBME) [7], which are typically identified in young children with an average age at diagnosis of 6 years, pituitary blastoma, which is a rare tumour described in children aged 2 years [7], and embryonal rhabdomyosarcoma (ERMS), which most commonly occurs in pubertal and post-pubertal adolescent girls and young women [7]. The syndrome is caused by mutations in the DICER1 gene, which is located on the long arm of chromosome 14 in region q32.13; its gene product (DICER1 protein) is a crucial component in the processing of microRNA (miRNA) [11].

Germline loss of function mutations in DICER1 have been identified in approximately 70–80% of children with PPB [12]. The presence of such germline mutations defines DICER1 PPB familial tumour predisposition syndrome (FTPS). DICER1 FTPS increases the risk for multiple tumour types, and the most severe manifestations of pathogenic germline DICER1 variants tend to present in early childhood, with adulthood characterised by good health [13]. Therefore, the follow-up of patients with PPB is important especially in children, and individuals should also continue to receive appropriate age-and gender-specific preventive screening studies and surveillance.

The DICER1 protein has a central role in development as a switch. Its function is ubiquitous in organogenesis, meaning that all organs are potential targets when this critical protein is faulty [14]. As a developmental switch in the lung, dysembrogenesis results in the formation of cysts which in the lung become PPB Type I. These cysts remain as such or undergo malignant progression to PPB type II or III [14]. The present study involved two pairs of monozygotic twins. Case 1 was twin girls aged 4 years 2 months with DICER1 mutation, one of whom developed PPB(II) and her identical sibling had acute transient hepatitis. As our previous study reported, whole-genome sequencing of blood samples identified 6,361,526 germline variants in this family (her mother and her sister), including the mutation identified by targeted sequencing (c.C3675A). In addition, the tumour tissue of Twin1 and Twin2 harbour a nonsynonymous variant of DICER1 (c.G5125A) [15]. However, no DICER1 mutations were found in Case 2 in the peripheral blood samples of either twin or their mother. Although recent studies have demonstrated that acute loss of DICER1

![Fig. 1 (a and b) Enhanced chest computed tomography (CT) scan revealed 5.9 x 4.8 x 7.6 cm heterogeneous solid lesion, multiple cystic liquefaction foci can be seen inside.](image)
leads to liver regeneration inhibition compared to WT littermates [16], and DICER1 germline mutation has a critical role in liver carcinogenesis [17], the relationship between the DICER1 gene and acute transient hepatitis is not yet clear. It is important to further explore whether DICER1 mutations have direct effects on hepatitis.

Inherited diseases are not always expressed in the same way in every individual that carries the same variant in a disease-causing gene. This phenomenon is known as reduced or incomplete penetrance [18]. Variable and incomplete penetrance may explain why clinically healthy individuals can carry potentially pathogenic variants without expressing features of the disease. DICER1 is inherited in an autosomal dominant manner with reduced penetrance. Study reported each child of an individual with a DICER1 germline pathogenic variant has a 50% chance of inheriting the variant, but given the reduced penetrance, many individuals with a germline DICER1 pathogenic variant remain clinically unaffected [19], they may explain why although twin1 and twin2 with DICER mutation, only twin1 developed PPB in our case1. Moreover, cancer is a set of diseases that exhibit not only genetic mutations but also a profoundly distorted epigenetic landscape, the epigenome has a crucial role in the regulation of gene expression, epigenetic changes such as DNA methylation. At the time of the twinning, both twins still have same methylation pattern. Over time, due to intrinsic and environmental factors, the pattern becomes markedly different. The one twin acquires methylation on the promoter site of the gene, which may influence expression and predispose this twin to cancer development [20].

The two PPB patients in the present study were girls. According to a previous study at our hospital [4], and the findings of Knight at el. PPB patients have an equal male-to-female ratio; whether there is no gender difference in monozygotic twins with PPB needs more clinical data support. The two pairs of twins were regularly followed up for 6 and 8 years, respectively and their condition had continued to be stable, but the weight and height of the PPB patients were significantly lower than that of their sister. The toxic effects of chemotherapy on growth are well known, during the phase of chemotherapy children often do not grow. T Moshang Jr. et al. reported that chemotherapy decrease growth velocity and causes growth arrest and bone age retardation and delays catch-up growth. As most of the growth in a child takes place before the age of 4 years and during puberty, it is likely that the effect of chemotherapy on growth will be most pronounced during these periods. One study has suggested that ifosfamide can bind with DNA to form DNA-DNA and DNA-protein cross-links, thus exerting a cytotoxic effect and inhibiting cell proliferation [21]; additionally, doxorubicin will trigger topoisomerase II activity to cause DNA damage [21]; therefore, both affect growth. In vitro studies also have shown doxorubicin and actinomycin D to have a direct effect on growth plate chondrocytes, that in animals resulted in decreased growth and final height [21]. In our study, both patients with PPB were in the growth phase at the time of chemotherapy and had received 12 cycles of chemotherapy with IVADO and IVA, resulting in cumulative doses of ifosfamide and doxorubicin of 48 g/m² and 240 mg/m², respectively. This dose of chemotherapy drugs might have affected the weight and height of the patients with PPB compared with their respective identical sister. Therefore, as the child enters adulthood, continued surveillance for growth and development is necessary.

The two pairs of monozygotic twins in our study were naturally conceived children. A trio-based analysis confirmed that they were monozygotic twins, as they have almost identical single nucleotide polymorphism genotypes (~99% identity). Until now, there have been no reports on whether the higher proportion of in vitro fertilisation (IVF) would cause a higher risk of PPB. The question of an increased cancer risk after IVF has been much debated. Spector et al. reported a small, marginally significant association between IVF and overall cancer in childhood and no association between IVF treatment and overall cancer or embryonal tumours [22]. Kaartinen N et al. also reported that the risk of childhood cancer did not appear to be increased in IVF children [23].

Several authors have pointed to a possible correlation between IVF and childhood cancer, mainly of neuroectodermal origin. Petridou et al. indicated the possible association between IVF and increased risk of early onset acute lymphocytic leukaemia (ALL) in children in Greece and Sweden [24], and Hargreave M et al. found that, among children born in Denmark, the use of frozen embryo transfer was associated with a small but statistically significant increased risk of childhood cancer compared to children born to fertile women [25]. A recent study found at most a small, marginally significant association between IVF and overall cancer in childhood in the United States; although this was the largest cohort published to date, this result did not definitively establish an association between IVF and tumours [26]. Therefore, although there may not be a higher risk of PPB arising from the higher proportion of in vitro fertilisation, continued follow-up of children conceived via IVF for cancer occurrence is warranted.

In Types II and III PPB, both systemic chemotherapy and surgical resection are critical components of treatment. Optimal timing for surgery and chemotherapy is dependent upon the type of PPB. Upfront resection is desirable in Type I/Ir tumours, with the decision to append chemotherapy onto treatment. For Type II/III tumours, consideration must be given to the anatomy of
the tumour itself: if a tumour is amenable to complete early resection, this approach is preferred. Indeed, up-front complete PPB resection at diagnosis is desirable when possible, but pre-operative chemotherapy may be necessary in instances where this is not possible or presents an unacceptable risk to the patient. For children with huge unresectable tumours, puncture biopsy or surgical biopsy can be performed first. After the lesion has been pathologically confirmed, the size of the tumour can be reduced by four to eight courses of chemotherapy followed by radical surgery [27].

In the present study, as the tumours were amenable to complete early resection at diagnosis, Twin1 underwent left lower lobectomy with complete removal and Twin3 underwent thoracotomy. Both patients received biopsy during the operation. Types II and III PPB require post-operative chemotherapy, and we used the protocol recommended by the International PPB Registry: ifosfamide, vincristine, actinomycin D and doxorubicin (IVAdo). The European Cooperative Study Group for Paediatric Rare Tumors (EXPeRT) has identified a threshold of 10 cm as a reasonable cut-off point, above which up-front biopsy followed by neoadjuvant chemotherapy is a reasonable approach. However, no prospective studies examining the timing of resection and chemotherapy exist.

This study reported the long-term follow-up of two pairs of monozygotic twins, now with stable health conditions. DICER1 testing is recommended for all individuals found to have a PPB of any type and should be performed for all first-degree relatives of patients with DICER1 mutations, with an emphasis on children under 7 years of age. PPB in one of monozygotic twins is rare, so we will continue to focus on the health condition of these twins closely in the future. Research on the molecular mechanism of PPB in these two cases will also be the subject of our future study.

Abbreviations
PPB: Pleuropulmonary blastoma; CT: Computed tomography; IVAdo: Ifosfamide, vincristine, actinomycin D, doxorubicin; IVA: Ifosfamide, vincristine, actinomycin D; US: Ultrasound; IVF: In vitro fertilisation

Acknowledgements
All authors would like to thank the patients and their parents.

Authors’ contributions
XLM designed the idea for this article and had managed the cases. SHZ collected clinical data and was a major contributor in writing the manuscript. All authors were involved in drafting, reviewing and approved the final version for submission.

Funding
This study was funded by National Science and Technology Key Projects (No. 2017ZX09304029). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
All data generated or analysed during this study are included in the published article.

Ethics approval and consent to participate
Patients and their parents provided written informed consent for the study. This case report was approved by ethics committees of the Ethics Committee of Beijing Children’s Hospital, Capital Medical University (2018-k-66).

Consent for publication
Written informed consents were obtained from the parents of the patients for publication of this case report, all information contained within it and any accompanying images. Copies of the written consents are available for review by the Editor of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in Children, Hematology Oncology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China. 2Children’s Hospital of Shanxi, Women health center of Shanxi, Taiyuan, Shanxi, China. 3Center for Clinical Epidemiology and Evidence-Based Medicine, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China. 4Department of Image Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China. 5Department of Pathology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China. 6Department of Thoracic Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China.

Received: 20 March 2020 Accepted: 29 September 2020
Published online: 07 October 2020

References
1. Nakatani Y, Koss KM, Kerr MN, et al. Pulmonary Blastoma. In: Travis WD, Brambilla E, Burke AP, et al., editors. WHO Classification of Tumours of Lung, Pleura, Thymus and Heart. 4th ed. Lyon: IARC, 2015. p. 93.
2. Priest JR, McDermott MB, Bhata S, Watterson J, Manvel JC, Dehner LP. Pleuropulmonary blastoma: a clinicopathologic study of 50 cases. Cancer. 1997;80(1):147–61.
3. Messinger YH, Stewart DR, Priest JR, et al. Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the international Pleuropulmonary Blastoma registry. Cancer. 2015;121:276–85.
4. Zhang N, Zeng Q, Ma X, Chen C, Yu J, Zhang X, Yan D, Xu C, Liu D, Zhang Q. Diagnosis and treatment of pleuropulmonary blastoma in children: A single-center report of 41 cases. J Pediatr Surg. 2020;55(7):1351–5.
5. Hill DA, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science. 2009;325(5943):965.
6. Doros L, Schultz KA, Stewart DR, Bauer AJ, Williams G, Rossi CT, Carr A, Yang J, Dehner LP, Messinger Y, Hill DA. DICER1-related disorders. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Meffdley K, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 2014. p. 1993–2020.
7. Schultz KAP, Williams GM, Kamihara J, Stewart DR, Harris AK, Bauer AJ, Turner J, Shah R, Schneider K, Schneider KW, Carr AG, Hamey LA, Baldinger S, Frazier AI, Orbach D, Schneider DT, Mallin D, Dehner LP, Messinger YH, Hill DA. DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies. Clin Cancer Res. 2018;24(10):2251–61. https://doi.org/10.1158/1078-0432.CCR-17-3089 Epub 2018 Jan 17. Review.
8. Li S, Cai S, Wang X, Zhang D, Fu L, Zeng Q, Peng X, Ma X. A pair of DICER1-positive monozygotic twins: One with pleuropulmonary blastoma, another with acute transient hepatitis. Pediatr Blood Cancer. 2017;64(12):e26680.
9. Holínová V, Drábová K, Nosková H, et al. DICER1 Syndrome. Klin Onkol. 2019;32:123–7.

10. Messinger YH, Stewart DR, Priest JR, Williams GM, Harris AK, Schultz KA, Yang J, Doros L, Rosenberg PS, Hill DA, Dehner LP. Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the international Pleuropulmonary Blastoma registry. Cancer. 2015;121:276–85.

11. De Kock L, Rivera B, Revil T, et al. Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma. Br J Cancer. 2017;116:1621–6.

12. Sabbaghian N, Silvestrini A, Hamel N, et al. Germ-line deletion in DICER1 revealed by a novel MLPA assay using synthetic oligonucleotides. Eur J Hum Genet. 2014;22(4):564–7.

13. Faure A, Atkinson J, Bouts A, Obrien M, Le Van G, Hutsong J, Helou Y. DICE R1 pleuropulmonary blastoma familial tumour predisposition syndrome: what the paediatric urologist needs to know. J Pediatr Urol. 2016 Feb;12(1): S–10.

14. Dehner LP, Schultz KA, Hill DA. Pleuropulmonary Blastoma: more than a lung neoplasm of childhood. Mo Med. 2019;116(3):206–10.

15. Cai S, Wang X, Zhao W, et al. DICER1 mutations in twelve Chinese patients with pleuropulmonary blastoma. Sci China Life Sci. 2017;60.

16. Lv T, Kong L, Jiang L, et al. Dicer1 facilitates liver regeneration in a manner dependent on the inhibitory effect of miR-21 on Pten and Rhob expression. Life Sci. 2019;232:116656.

17. Caruso S, Calderaro J, Letouzé E, et al. Germline and somatic DICER1 mutations in familial and sporadic liver tumors. J Hepatol. 2017;66(4):734–42.

18. Taeubner J, Wieczorek D, Yasin L, Brozou T, Borkhardt A, Kuhl M. Penetrance and expressivity in inherited Cancer predisposing syndromes. Trends Cancer. 2018;4(11):718–28.

19. Schultz KAP, Stewart DR, Kamihara J, et al. DICER1 Tumor Predisposition. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2014.

20. Roos L, Spector TD, Bell CG. Using epigenomic studies in monozygotic twins to improve our understanding of cancer. Epigenomics. 2014;6(3):299–309. https://doi.org/10.2217/epi.14.13.

21. van Leeuwen BL, Kamps WA, Jansen HW, Hoekstra HJ. The effect of chemotherapy on the growing skeleton. Cancer Treat Rev. 2000;26(5):363–76.

22. Spector LG, Brown MB, Wantman E, et al. Association of in Vitro Fertilization with Childhood Cancer in the United States. JAMA Pediatr. 2019;173(6): e190392.

23. Kaartinen N, Tinkanen H. Do in vitro fertilization treatments result in healthy babies? Duodecim. 2017;133(8):278–34.

24. Petridou ET, Sergentanis TN, Panagopoulou P, et al. In vitro fertilization and risk of childhood leukemia in Greece and Sweden. Pediatr Blood Cancer. 2012;58(6):930–6.

25. Hargreave M, Jensen A, Hansen MK, et al. Association between fertility treatment and Cancer risk in children. JAMA. 2019;322(22):2203–10.

26. Spector LG, Brown MB, Wantman E, Letterie GS, Toner JP, Doody K, Ginsburg E, Williams M, Koch L, Schymura MJ, Luke B. Association of in vitro fertilization with childhood cancer in the United States. JAMA Pediatr. 2019;173(6):e190392.

27. Knight S, Knight T, Khan A, Murphy AJ. Current management of pleuropulmonary blastoma surgical perspective. Children (Basel). 2019;6(8). pii: E86.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.